Low 25-OH Vitamin D is Associated with Benign Prostatic Hyperplasia

No AccessJournal of UrologyAdult Urology1 Aug 2013Low 25-OH Vitamin D is Associated with Benign Prostatic Hyperplasia Mohammad-Ali Haghsheno, Dan Mellström, Carl-Johan Behre, Jan-Erik Damber, Helena Johansson, Magnus Karlsson, Mattias Lorentzon, Ralph Peeker, Elisabet Barret-Connor, Ewa Waern, Valter Sundh, Claes Ohlsson, and Jan Hammarsten Mohammad-Ali HaghshenoMohammad-Ali Haghsheno Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Dan MellströmDan Mellström Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Carl-Johan BehreCarl-Johan Behre Department of Internal Medicine, Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden More articles by this author , Jan-Erik DamberJan-Erik Damber Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Helena JohanssonHelena Johansson Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Magnus KarlssonMagnus Karlsson Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Orthopaedic Surgery, Skåne University Hospital in Malmö, Lund University, Malmö, Sweden More articles by this author , Mattias LorentzonMattias Lorentzon Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Ralph PeekerRalph Peeker Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden Financial interest and/or other relationship with Astellas, Lilly, Pfizer, Bayer and AstraTech. More articles by this author , Elisabet Barret-ConnorElisabet Barret-Connor Department of Family and Preventive Medicine, University of California-San Diego, San Diego, California More articles by this author , Ewa WaernEwa Waern Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Valter SundhValter Sundh Department of Community Medicine and Public Health, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , Claes OhlssonClaes Ohlsson Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author , and Jan HammarstenJan Hammarsten Section of Urology, Department of Surgery, Karlstad Central Hospital, Karlstad, Sweden More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.01.104AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We tested the hypothesis that low vitamin D is associated with benign prostatic hyperplasia. We also studied whether body composition, sex hormones, serum sex hormone-binding globulin, albumin corrected serum calcium, adiponectin and lipid status are associated with benign prostatic hyperplasia. Materials and Methods: We investigated 184 representative, randomly selected men 72 to 76 years old enrolled in the Gothenburg arm of the Osteoporotic Fractures in Men Study (MrOS). Men with a history of prostate cancer, prostate operation or medication for benign prostatic hyperplasia were excluded from study, leaving 155 available for analysis. A cross-sectional study was performed in which benign prostatic hyperplasia measured by total prostate volume was related to clinical, anthropometric, endocrine and metabolic factors on univariate and multivariate analyses with regression models. Results: Median prostate volume was 40 ml. In multivariate models only 25-OH vitamin D, albumin corrected serum calcium, serum sex hormone-binding globulin and high density lipoprotein cholesterol were significantly and inversely associated with large prostate glands. Conclusions: The current report adds 4 independent factors associated with benign prostatic hyperplasia, including low 25-OH vitamin D, serum calcium, sex hormone-binding globulin and high density lipoprotein cholesterol. References 1 : Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol2013; 23: 5. Google Scholar 2 : The correlation between metabolic syndrome and prostatic diseases. Eur Urol2012; 61: 560. Google Scholar 3 : Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis1998; 1: 157. Google Scholar 4 : The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol2007; 51: 199. Google Scholar 5 : Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis2009; 12: 160. Google Scholar 6 : Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia. Eur Urol2001; 39: 151. Google Scholar 7 : Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol2002; 168: 599. Link, Google Scholar 8 : Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta2006; 370: 89. Google Scholar 9 : Review: The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab2007; 92: 2017. Google Scholar 10 : Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet2002; 360: 57. Google Scholar 11 : Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res1994; 54: 805. Google Scholar 12 : Adiponectin and cancer: a systematic review. Br J Cancer2006; 94: 1221. Google Scholar 13 : Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology2003; 144: 3046. Google Scholar 14 : Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol2004; 150: 591. Google Scholar 15 : BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol2006; 49: 82. Google Scholar 16 : Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol2008; 167: 925. Google Scholar 17 : Determination of prostate volume by transrectal ultrasound. J Urol1991; 145: 984. Link, Google Scholar 18 : Low serum vitamin D is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int2012; 23: 991. Google Scholar 19 : Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Min Res2007; 22: 220. Google Scholar 20 : High serum adiponectin predicts incident fractures in elderly men: osteoporotic fractures in men (MrOS) Sweden. J Bone Miner Res2012; 27: 1390. Google Scholar 21 : Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment. BJU Int2012; 110: E857. Google Scholar 22 : Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prevent2011; 20: 1850. Google Scholar 23 : Vitamin D and the epidemiology of prostate cancer. Semin Dialysis2005; 18: 276. Google Scholar 24 : Sunlight, season, skin pigmentation, vitamin D, and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am J Clin Nutr1998; 67: 1108. Google Scholar 25 : Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev1998; 7: 391. Google Scholar 26 : Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol1998; 66: 121. Google Scholar 27 : Vitamin D as a promising anticancer agent. Indian J Pharmacol2011; 43: 113. Google Scholar 28 : Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation2011; 82: 184. Google Scholar 29 : Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev2010; . CD006015. Google Scholar 30 : Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J Urol2010; 184: 1040. Link, Google Scholar © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byYuan P, Wang T, Li H, Lan R, Li M and Liu J (2020) Systematic Review and Meta-Analysis of the Association between Vitamin D Status and Lower Urinary Tract SymptomsJournal of Urology, VOL. 205, NO. 6, (1584-1594), Online publication date: 1-Jun-2021.Kaplan S (2018) Re: Vitamin D Deficiency as a Potential Marker of Benign Prostatic HyperplasiaJournal of Urology, VOL. 200, NO. 5, (919-920), Online publication date: 1-Nov-2018.Kaplan S (2017) Re: Hypovitaminosis D is Associated with Lower Urinary Tract Symptoms and Benign Prostate Hyperplasia in Type 2 DiabetesJournal of Urology, VOL. 198, NO. 2, (224-225), Online publication date: 1-Aug-2017.Kaplan S (2016) Re: Systematic Review and Meta-Analysis of Candidate Gene Association Studies of Lower Urinary Tract Symptoms in MenJournal of Urology, VOL. 195, NO. 6, (1839-1840), Online publication date: 1-Jun-2016. Volume 190Issue 2August 2013Page: 608-614 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.Keywordsprostatic hyperplasiavitamin Dprostatelipoproteins, HDLsex hormone-binding globulinMetricsAuthor Information Mohammad-Ali Haghsheno Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Dan Mellström Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Carl-Johan Behre Department of Internal Medicine, Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden More articles by this author Jan-Erik Damber Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Helena Johansson Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Magnus Karlsson Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Orthopaedic Surgery, Skåne University Hospital in Malmö, Lund University, Malmö, Sweden More articles by this author Mattias Lorentzon Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Ralph Peeker Department of Urology, Institute of Clinical Sciences, Sahlgrenska University Hospital, Goteborg, Sweden Financial interest and/or other relationship with Astellas, Lilly, Pfizer, Bayer and AstraTech. More articles by this author Elisabet Barret-Connor Department of Family and Preventive Medicine, University of California-San Diego, San Diego, California More articles by this author Ewa Waern Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Valter Sundh Department of Community Medicine and Public Health, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Claes Ohlsson Centre for Bone and Arthritis Research at the Sahlgrenska Academy, Sahlgrenska University Hospital, Goteborg, Sweden More articles by this author Jan Hammarsten Section of Urology, Department of Surgery, Karlstad Central Hospital, Karlstad, Sweden More articles by this author Expand All Advertisement PDF downloadLoading ...